Rob Reed

Rob Reed has extensive experience in the field of research and development for medical diagnostic companies. Rob started their career at Quidel, where they held various roles such as Research Associate and R&D Director. At Quidel, they spearheaded the development of several lateral-flow immunoassay projects, including the first FDA emergency use authorized SARS-CoV-2 rapid antigen test. Rob also developed other tests for infectious diseases and Lyme disease.

Before joining Quidel, Reed worked at Trinity Biotech as an R&D Scientist. There, they managed a start-up lateral-flow immunoassay research and development group and led the development of several infectious disease lateral flow tests.

Prior to Trinity Biotech, Reed worked at Genzyme as a Staff Scientist. In this role, they played a primary role in developing various lateral-flow immunoassay projects, including tests for Influenza, Respiratory Syncitial Virus, stroke, and cardiac conditions.

Reed began their career at Qualigen Inc. as a Research Associate, where they developed a quantitative chemiluminescent LH immunoassay and successfully retrofitted a preliminary tube assay into a chemiluminescent analyzer.

Before Qualigen, Reed worked at Acon Laboratories as a Research Associate, where they were involved in the research and development of immunologically based Chlamydia, Strep A, and LH one-step lateral flow assays. Rob led the Chlamydia team and coordinated sales/marketing, regulatory, manufacturing, and R&D efforts.

Throughout their career, Reed has gained expertise in assay development, project management, team leadership, technology transfer, and validation. Rob has experience with various sample types and has worked in GLP/GMP environments.

Rob Reed received a Bachelor of Science (B.S.) degree in Microbiology, General from UC San Diego, which they completed between 1991 and 1995.